Skip to main content .
EXPANDING PHARMACEUTICAL MANUFACTURING IN THE UNITED STATES Support Services MCM Manufacturing Clinical Trials
BARDA’s Expanding
COVID-19 Medical Countermeasure Portfolio

BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.

Envelope icon Follow Us

Be the first to get updated on the progress of BARDA Portfolio Partners. Sign-up for our email announcements:

BARDA'S Impact of Diagnostic Investments

Rapidly deploying test kits to Americans

115.1M+
Diagnostic Test Kits Shipped by Partners
*as of April 30, 2021

Doing Business with BARDA

BARDA BAA: COVID-19 Areas of Interest

BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003).

Learn More

Doing Business with BARDA

Novel Coronavirus EZ-BAA

To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak.

Learn More

Doing Business with BARDA

2019 Novel Coronavirus Federal Market Research Initiative

If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners!

Learn More

Website Refresh

www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov